Cardiol Therapeutics Class Stock Today
| CRDL Stock | USD 1.12 0.07 5.88% |
PerformanceVery Weak
| Odds Of DistressAverage
|
Cardiol Therapeutics is selling for 1.12 as of the 22nd of March 2025. This is a 5.88% down since the beginning of the trading day. The stock's lowest day price was 1.12. Cardiol Therapeutics has 54 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 20th of February 2025 and ending today, the 22nd of March 2025. Click here to learn more.
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease . Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada. The company has 81.6 M outstanding shares of which 1.48 M shares are currently shorted by private and institutional investors with about 7.13 trading days to cover. More on Cardiol Therapeutics Class
Moving together with Cardiol Stock
| 0.64 | VTRS | Viatris | PairCorr |
| 0.71 | NBIX | Neurocrine Biosciences | PairCorr |
| 0.78 | ELAN | Elanco Animal Health | PairCorr |
Moving against Cardiol Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Cardiol Stock Highlights
| CEO President | David MBA |
| Business Concentration | Pharmaceutical Products, Drug Manufacturers - Specialty & Generic, Healthcare, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) |
Cardiol Therapeutics Class (CRDL) is traded on NASDAQ Exchange in USA. It is located in 2265 Upper Middle Road East, Oakville, ON, Canada, L6H 0G5 and employs 7 people. Cardiol Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 92.03 M. Cardiol Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 81.6 M outstanding shares of which 1.48 M shares are currently shorted by private and institutional investors with about 7.13 trading days to cover.
Cardiol Therapeutics Class currently holds about 70.45 M in cash with (25.18 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.14, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Cardiol Therapeutics Probability Of Bankruptcy
Ownership AllocationCardiol Therapeutics holds a total of 81.6 Million outstanding shares. Cardiol Therapeutics Class shows 4.0 percent of its outstanding shares held by insiders and 12.18 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cardiol Ownership Details
Cardiol Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Cardiol Therapeutics market risk premium is the additional return an investor will receive from holding Cardiol Therapeutics long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.01) | |||
| Jensen Alpha | (0.07) | |||
| Total Risk Alpha | 0.2427 | |||
| Treynor Ratio | (0.31) |
Cardiol Stock Against Markets
Cardiol Therapeutics Corporate Management
| Andrew MD | Chief Development | Profile | |
| Trevor Burns | Investor Relations | Profile | |
| Bernard BSc | Chief Officer | Profile | |
| MBA BSCPT | Vice Development | Profile | |
| MBA MBA | CEO Pres | Profile | |
| CA CMA | Corp CFO | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiol Therapeutics. If investors know Cardiol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiol Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cardiol Therapeutics is measured differently than its book value, which is the value of Cardiol that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiol Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cardiol Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiol Therapeutics' market value can be influenced by many factors that don't directly affect Cardiol Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiol Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.